AJMC: Your study found that emphysema affecting at least 20% of the lung on CT was consistently associated with differences ...
The randomized controlled period (RCP) in the phase 3 MINT trial of inebilizumab for myasthenia gravis (MG) wasn't reported ...
Switching Medicare Advantage (MA) plans is increasingly common among MA enrollees, especially those dually eligible for ...
1. ZANVASTRO (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results